Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

The following are the claims listed for the second patent that will expire in less than 11 months.

What is claimed is:

1. A method of purifying a cancer antigen comprising:

isolating a sample which includes ring shape particle;

collecting proteins from the sample; and

contacting the collected proteins with an affinity chromatography medium specific for proteins with a dinucleotide fold.

2. A method of purifying a universal tumor marker characterized by ring shaped particles comprising:

precipitating proteins from serum, wherein the serum is prepared from a patient suffering from cancer, with about 50% (saturation) ammonium sulfate;

collecting the precipitate;

dissolving the collected precipitate in a liquid medium;

applying the dissolved precipitate to a gel filtration medium;

collecting fractions from the gel filtration medium which bind to tRNA, to form gel filtration purified material;

applying the gel filtration purified material to a calcium phosphate gel;

washing the calcium phosphate gel and gel filtration purified material to remove unbound material;

eluting material from the calcium phosphate gel;

collecting fractions from the calcium phosphate gel which bind to tRNA, to form calcium phosphate gel purified material;

binding the calcium phosphate gel purified material to a cibicron blue containing chromatography medium;

washing the cibicron blue containing chromatography medium and the calcium phosphate gel purified material to remove unbound material;

eluting material from the cibicron blue containing chromatography medium; and

collecting fractions from the cibicron blue containing chromatography medium which bind tRNA, to form universal tumor marker.

3. A method as recited in claim 2 further comprising re-precipitating proteins from the dissolved precipitate with about 50% (saturation) ammonium sulfate.

4. A method as recited in claim 2 wherein the precipitate is dissolved in a buffer comprising about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide.

5. A method as recited in claim 2 wherein the gel filtration medium is equilibrated with about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide.

6. A method as recited in claim 2 wherein calcium phosphate gel is equilibrated with about 25 mM potassium phosphate, pH 6.8, about 1 mM dithiothreitol and about 20% (v/v) glycerol.

7. A method as recited in claim 2 wherein the calcium phosphate gel is eluted with a linear gradient from about 100 to about 150 mM potassium phosphate, pH 6.8, in about 1 mM dithiothreitol and about 20% (v/v) glycerol.

8. A method as recited in claim 2 wherein the cibicron blue containing chromatography medium is equilibrated with about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide.

9. A method as recited in claim 2 wherein the cibicron blue containing chromatography medium is eluted with a linear gradient from about 0 to about 0.6M potassium chloride in about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide.

10. A method of purifying a universal tumor marker characterized by ring shaped particles comprising:

precipitating proteins from serum, wherein the serum is prepared from of a patient suffering from cancer, with about 50% (saturation) ammonium sulfate;

collecting the precipitate;

dissolving the collected precipitate in a buffer comprising about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;

precipitating proteins from the dissolved precipitate with about 50% (saturation) ammonium sulfate;

collecting the precipitate;

dissolving the collected precipitate in a buffer comprising about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;

applying the dissolved precipitate to a gel filtration medium wherein the gel filtration medium is equilibrated with about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;

collecting fractions from the gel filtration medium which bind to tRNA, to form gel filtration purified material;

applying the gel filtration purified material to a calcium phosphate gel wherein the calcium phosphate gel is equilibrated with about 25 mM potassium phosphate, pH 6.8, about 1 mM dithiothreitol and about 20% (v/v) glycerol;

washing the calcium phosphate gel and gel filtration purified material to remove unbound material;

eluting material from the calcium phosphate gel with a linear gradient from about 100 to about 150 mM potassium phosphate, pH 6.8, in about 1 mM dithiothreitol and about 20% (v/v) glycerol;

collecting fractions from the calcium phosphate gel which bind to tRNA, to form calcium phosphate gel purified material;

binding the calcium phosphate gel purified material to a cibicron blue containing chromatography medium wherein the cibicron blue containing chromatography medium is equilibrated with about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;

washing the cibicron blue containing chromatography medium and the calcium phosphate gel purified material to remove unbound material;

eluting material from the cibicron blue containing chromatography medium with a linear gradient from about 0 to about 0.6M potassium chloride in about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide; and

collecting fractions from the cibicron blue containing chromatography medium which bind tRNA, to form universal tumor marker.

11. A universal tumor marker produced by the method of claim 2.

12. A universal tumor marker produced by the method of claim 10.